Nesina and Uloric drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nesina (alogliptin benzoate) and Uloric (febuxostat). Common drug interactions include diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Nesina and Uloric. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Nesina?

Nesina has active ingredients of alogliptin benzoate. eHealthMe is studying from 2,297 Nesina users. Check the latest studies of Nesina.

What is Uloric?

Uloric has active ingredients of febuxostat. It is often used in gout. eHealthMe is studying from 8,067 Uloric users. Check the latest studies of Uloric.



On Jul, 26, 2026

13 people who take Nesina and Uloric together, and have interactions are studied.

Nesina and Uloric drug interactions.

What are the common drug interactions of Nesina and Uloric, by gender? *:

female:

n/a

male:

  1. Diarrhoea
  2. Tonsil cancer
  3. Appetite disorder (abnormal eating habits)
  4. Constipation
  5. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)
  6. Abdominal distension
  7. Abdominal rigidity
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Nausea (feeling of having an urge to vomit)
  10. Rectal haemorrhage (bleeding from anus)

What are the common drug interactions of Nesina and Uloric, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Constipation
  2. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)

50-59:

n/a

60+:

  1. Tonsil cancer
  2. Appetite disorder (abnormal eating habits)
  3. Diarrhoea

What are the existing conditions these people have? *

  1. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 8 people, 61.54%
  2. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 5 people, 38.46%
  3. Indigestion: 4 people, 30.77%

* Approximation only. Some reports may have incomplete information.

Do you take Nesina and Uloric?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Nesina and Uloric:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nesina:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Uloric:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nesina and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Uloric and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on alogliptin benzoate and febuxostat (the active ingredients of Nesina and Uloric, respectively), and Nesina and Uloric (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: